The phase 3 trial evaluated fenfluramine when used as an adjunctive therapy for the treatment of uncontrolled seizures in children and adults aged 1 year to 35 years with CDD.

The Breyanzi REMS program and the Abecma REMS program were established due to the risk of cytokine release syndrome and neurologic toxicities.

Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.